All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a healthcare professional.
The PsOPsA Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your PsOPsA Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe PsOPsA Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the PsOPsA Hub cannot guarantee the accuracy of translated content. The PsOPsA Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The PsOPsA Hub is supported by educational grants. All educational content is developed independently by SES in collaboration with our expert steering committee, with no input or influence from financial supporters. We would like to express our gratitude to the following companies for their support: • UCB: For website development, launch, and ongoing maintenance. • UCB and Bristol Myers Squibb: For educational content and news updates.
Biomarkers associated with response in PsA: A phase II trial of deucravacitinib
By Ella Dixon
|
Deucravacitinib, a TYK2 inhibitor, has demonstrated efficacy in both PsO and PsA, and is approved in multiple countries for adult patients with plaque PsO.1 An analysis of a phase II trial of deucravacitinib, which evaluated biomarker association with disease activity, pharmacodynamics, and clinical responses, was published in Arthritis and Rheumatology by FitzGerald et al.1 A total of 203 patients with PsA were assigned 1:1:1 to deucravacitinib 6 mg, deucravacitinib 12 mg, or placebo. Biomarkers, including those associated with the IL-23 pathway, and clinical responses, including PASI 75 and ACR 20, were assessed at Week 16.1 |
| Key learnings |
|
Elevated serum levels of IL-17A, BD-2, and IL-19 were significantly associated with higher baseline disease activity in PsA, including skin disease severity as measured by PASI. |
|
Deucravacitinib treatment significantly reduced levels of IL-17A, BD-2, IL-19, and other inflammatory biomarkers by Week 16, indicating suppression of inflammatory pathways. |
|
Patients with higher baseline levels of IL-23 pathway-associated biomarkers were more likely to achieve clinical improvement after deucravacitinib treatment, as evidenced by PASI 75 and ACR 20 responses. |
|
This study suggests that assessing IL-23 pathway-associated biomarkers could guide therapeutic decisions in PsA, identifying patients who might benefit most from deucravacitinib and allow for personalized therapy. |
Abbreviations: ACR 20, 20% improvement in American College of Rheumatology response; BD2, β-defensin 2; IL, interleukin; PASI 75, 75% improvement in Psoriasis Area and Severity Index; PsA, psoriatic arthritis; PsO, psoriasis; TYK2, tyrosine kinase 2.
- FitzGerald O, Gladman D, Mease P, et al. Phase 2 Trial of Deucravacitinib in Psoriatic Arthritis: Biomarkers Associated With Disease Activity, Pharmacodynamics, and Clinical Responses. Arthritis Rheumatol. 2024;76(9):1397-1407. DOI: 10.1002/art.42921
More about...
Your opinion matters
10 votes - 50 days left ...
Related articles
Newsletter
Subscribe to get the best content related to Psoriasis and Psoriatic Arthritis delivered to your inbox